PD/4-32804/A

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087141 A1

(51) International Patent Classification[7]: A61K 31/435, 31/436, 47/02, 47/10, 47/14, 47/44

(21) International Application Number: PCT/EP2004/003513

(22) International Filing Date: 2 April 2004 (02.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0307866.4 4 April 2003 (04.04.2003) GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HIRSCH, Stefan** [DE/DE]; Theodor-Heuss-Strasse 21A, 79539 Lörrach (DE). **MAYER, Friedrich, Karl** [AT/CH]; Im Ziegelgarten 9, CH-4104 Oberwil (CH). **PAUL, Carle** [FR/FR]; 20, rue du Sundgau, F-68100 Mulhouse (FR). **SEKKAT, Nabila** [MA/CH]; Davidsbodenstrasse 34, CH-4056 Basel (CH). **WEISS, Carl-Martin** [DE/DE]; Ritterstrasse 57a, 79541 Lörrach-Haagen (DE).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectuel Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING AN IMMUNOSUPPRESSANT FOR USE IN THE TREATMENT OF SKIN DISEASES

(57) Abstract: Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an emollient such as dimethicone, glycerol or isostearyl isostearate are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as dry skin or atopic or contact dermatitis.

WO 2004/087141 A1

PHARMACEUTICAL COMPOSITION COMPRISING AN IMMUNOSUPPRESSANT FOR USE IN THE TREATMENT OF SKIN DISEASES

The invention relates to pharmaceutical compositions, for use in particular in the treatment of skin diseases. It concerns a pharmaceutical composition comprising a macrolide T-cell immunomodulator or immunosuppressant and an emollient.

It has now been found that, surprisingly, macrolide T-cell immunomodulators and immunosuppressants, when used in combination or association with emollients, act synergistically, resulting in a potentiation of pharmacological activity, such that effective beneficial, especially anti-dermatitis activity is seen upon co-administration at dosages which would be well below the effective dosages administered individually.

The invention thus concerns novel pharmaceutical compositions comprising a **macrolide T-cell immunomodulator or immunosuppressant** in association or combination with an **emollient**, hereinafter briefly named "the compositions of the invention".

A macrolide T-cell immunomodulator or immunosuppressant is to be understood herein as being a T-cell immunomodulator or T-cell immunosuppressant which has a macrocyclic compound structure including a lactone or lactam moiety. While it preferably has at least some T-cell immunomodulating or immunosuppressant activity, it may also exhibit concomitantly or predominantly further pharmaceutical properties, such as anti-inflammatory activity.

An emollient is to be understood herein as being an agent which softens or soothes the skin, or soothes an irritated internal surface.

It should be appreciated that the present invention does not contemplate merely the inclusion of an emollient as a minor excipient in a pharmaceutical composition comprising a macrolide T-cell immunomodulator or immunosuppressant in order to e.g. improve the compatibility of the composition as such with e.g. human skin. More comprehensively, it is contemplated herewith to involve emollients as active agents in their own right, whereby "active" should be understood as relating not only to pharmacological activity, but also activity as regards cosmetic aspects, such as the appearance or brittleness of skin.

The amount of emollient to be used or included with the compositions of the invention is thus normally substantially more than commonly used in pharmaceutical

compositions, or is administered separately from the macrolide. It is e.g. from about 10 % to about 5000 %, preferably from about 20 % to about 1000 %, more preferably from about 100 % to about 500 % w/w of the amount of macrolide in the composition.

The compositions of the invention may thus be viewed also as health care or personal care products incorporating at least one pharmaceutically active component, or as so-named "cosmeceuticals".

The compositions of the invention may be adapted for systemic use as regards the immunomodulator or immunosuppressant component, e.g. oral or intravenous, or for topical use for both components; preferably they are adapted for topical use. They are useful for the known indications of the particular active agents incorporated therein. They are particularly indicated for use in dermatological or mucosal diseases, e.g. dermatological or mucosal diseases which have an inflammatory component or involve inflammatory complications, such as dry skin or atopic or contact dermatitis.

The composition resulting from the combination is e.g. a medicated emollient, appropriately presented, e.g. as a poultice or a cataplasm.

A suitable **macrolide T-cell immunomodulator or immunosuppressant** is for example an FKBP12-binding calcineurin inhibitor or mitogen-activated kinase modulator or inhibitor, in particular an **asco-** or **rapamycin**. It preferably is an ascomycin. While the macrolide preferably has at least some calcineurin- or mitogen-activated kinase modulating or inhibiting activity, it may also exhibit concomitantly or predominantly further pharmaceutical properties, such as antiinflammatory activity. It preferably is a compound, e.g. an ascomycin, having rather long-acting activity relatively to other members of the same structural class, e.g. it is metabolically degraded slowly to inactive products.

An asco- or rapamycin is to be understood as asco- or rapamycin as such, or a derivative thereof. An asco- or rapamycin derivative is to be understood as being an antagonist, agonist or analogue of the parent compound which retains the basic structure and modulates at least one of the biological, for example immunological properties of the parent compound.

An "anti-inflammatory ascomycin derivative" is defined herein as an ascomycin derivative that exhibits pronounced anti-inflammatory activity in e.g. animal models of allergic

contact dermatitis but has only low potency in suppressing systemic immune response, namely, which has a minimum effective dose (MED) of up to a concentration of about 0.04 % w/v in the murine model of allergic contact dermatitis upon topical administration, while its potency is at least 10 times lower than for tacrolimus (MED 14 mg/kg) in the rat model of allogeneic kidney transplantation upon oral administration (Meingassner, J.G. et al., Br. J. Dermatol. 137 [1997] 568-579; Stuetz, A. Seminars in Cutaneous Medicine and Surgery 20 [2001] 233-241). Such compounds are preferably lipophilic.

Suitable **ascomycins** are e.g. as described in EP 184162, EP 315978, EP 323042, EP 423714, EP 427680, EP 465426, EP 474126, WO 91/13889, WO 91/19495, EP 484936, EP 523088, EP 532089, EP 569337, EP 626385, WO 93/5059 and WO 97/8182;
in particular:

- **ascomycin**;
- **tacrolimus** (FK506; Prograf^{R});
- **imidazolylmethoxyascomycin** (WO 97/8182 in Example 1 and as compound of formula I);
- **32-O-(1-hydroxyethylindol-5-yl)ascomycin** (L-732531) (Transplantation 65 [1998] 10-18, 18-26, on page 11, Figure 1; and
- **(32-desoxy-32-epi-N1-tetrazolyl)ascomycin** (ABT-281) (J.Invest.Dermatol. 12 [1999] 729-738, on page 730, Figure 1);

preferably:

- {1R,5Z,9S,12S-[1E-(1R,3R,4R)],13R,14S,17R,18E,21S,23S,24R,25S,27R}-17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0(4,9)]octacos-5,18-diene-2,3,10,16-tetraone (Example 8 in EP 626385),
  hereinafter referred to as "**5,6-dehydroascomycin**";
- {1E-(1R,3R,4R)]1R,4S,5R,6S,9R,10E,13S,15S,16R,17S,19S,20S}-9-ethyl-6,16,20-trihydroxy-4-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-15,17-dimethoxy-5,11,13,19-tetramethyl-3-oxa-22-azatricyclo[18.6.1.0(1,22)]heptacos-10-ene-2,8,21,27-tetraone (Examples 6d and 71 in EP 569337), hereinafter referred to as "**ASD 732**";
  and especially

- **pimecrolimus** (INN recommended) (ASM981; Elidel™), i.e. {[1E-(1R,3R,4S)]1R,9S,12S, 13R,14S,17R,18E, 21S,23S,24R,25S,27R}-12-[2-(4-chloro-3-methoxycyclohexyl)-1-methylvinyl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28,dioxa-4-azatricyclo [22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetraone, of formula I



(Example 66a in EP 427680),

hereinafter also referred to as "**33-epichloro-33-desoxyascomycin**".

Suitable anti-inflammatory ascomycin derivatives are e.g.: (32-desoxy-32-epi-N1-tetrazolyl)ascomycin (ABT-281); 5,6-dehydroascomycin; ASD 732; and pimecrolimus.

Suitable **rapamycins** are e.g. as described in USP 3'929'992, WO 94/9010 and USP 5'258'389, preferably **sirolimus** (rapamycin; Rapamune^{R}) and **everolimus** (RAD001; Certican^{R}).

A particularly preferred macrolide T-cell immunomodulator or immunosuppressant is **pimecrolimus**; it is in free form unless specified otherwise.

A suitable **emollient** is for example one-phase mineral oil (petrolatum), or mineral oil as a two-phase system, either as an oil-in-water or a water-in-oil emulsion, or as a lotion; it is e.g. a silicone such as dimethicone; glycerine; or vaseline. The system may be of low or high viscosity. It may form a hydrophobic protective film on the skin, as with e.g. a silicone such as dimethicone, or paraffin or petrolatum (vaseline). A humectant may be added as appropriate, e.g. glycerol; or an emollient which has semi-occlusive properties may be used,

such as a fatty acid or a fatty acid ester, e.g. isostearyl isostearate. Preferred emollients are dimethicone, glycerol and isostearyl isostearate.

Emollients may thus be e.g. fatty alcohols, hydrocarbons, triglycerides, waxes, esters, silicone oils and lanolin containing products. Fatty alcohols are e.g. cetyl alcohol, octyldodecanol, stearyl alcohol and oleyl alcohol. Hydrocarbons include mineral oil, petrolatum, paraffin, squalene, polybutene, polyisobuten, hydrogenated polyisobutene, cerisin and polyethylene. Triglycerides are e.g. castor oil, caprylic/capric triglyceride, hydrogenated vegetable oil, sweet almond oil, wheat germ oil, sesame oil, hydrogenated cottonseed oil, coconut oil, wheat germ glycerides, avocado oil, corn oil, trilaurin, hydrogenated castor oil, shea butter, cocoa butter, soybean oil, mink oil, sunflower oil, safflower oil, macadamia nut oil, olive oil, apricot kernel oil, hazelnut oil and borage oil. Waxes include e.g. carnauba wax, beeswax, cadelilla wax paraffin, Japan wax, microcrystalline wax, jojoba oil, cetyl esters wax, and synthetic jojoba oil. Esters include e.g. isopropyl myristate, isopropyl palmitate, octyl palmitate, isopropyl linoleate, C_{12-15} alcohol benzoates, cetyl palmitate, myristyl myristate, myristyl lactate, cetyl acetate, propylene glycol dicaprylate/caprate, decyl oleate, stearyl heptanoate, diisostearyl malate, octyl hydroxystearate and isopropyl isostearate. Silicone oils are e.g. dimethicone (dimethyl polysiloxane) and cyclomethicone. Lanolin containing products are e.g. lanolin, lanolin oil, isopropyl lanolate, acetylated lanolin alcohol, acetylated lanolin, hydroxylated lanolin, hydrogenated lanolin and lanolin wax.

Personal care products are e.g. shampoos, hair conditioners, combination shampoo/conditioner, shower gels, soaps, hair styling products, hair colorants, deodorants, antiperspirants and moisturizing lotions. The compositions of the invention may comprise, in addition, further active components which provide benefit to the hair or skin, e.g. moisturizing agents, antiperspirants, anti-bacterials, cleaning agents, hair conditioning agents, hair styling agents, anti-dandruff agents, hair growth promoters, hair dyes and pigments, soaps and perfumes.

The compositions of the invention may be e.g. creamy, of the "light" or "rich" type, or greasy, or containing urea. Further components may be selected from e.g. almond oil, cacao butter, castor oil, decyl oleate, triglyceride, cetostearyl ethylhexanoate, stearyl heptanoate or caprylate, diisopropyl adipate, tri-isononanoin, polyethyleneglycol-40 butyloctanol and trideceth-9, polyethyleneglycol-5-ethylhexanoate.

Subgroups of compositions of the invention comprise a macrolide T-cell immunomodulator or immunosuppressant, preferably an anti-inflammatory ascomycin derivative as defined above, especially pimecrolimus, in combination or association with an emollient other than the following emollients singly or collectively in any number:

- glycerine; and/or
- a fatty acid ester; and/or
- a silicone; and/or
- dimethicone; and/or
- a fatty acid; and/or
- petrolatum.

In a further subgroup of compositions of the invention the macrolide T-cell immunomodulator or immunosuppressant is other than tacrolimus; in a further subgroup it is other than tacrolimus and sirolimus.

Preferred for use in the treatment of conditions where inflammation is involved are compositions of the invention wherein one or both components possess some degree of inherent anti-inflammatory activity. Particularly preferred are compositions comprising an ascomycin, preferably an anti-inflammatory ascomycin derivative, especially pimecrolimus, in combination or association with an emollient; more especially pimecrolimus in combination or association with dimethicone, glycerol or isostearyl isostearate. The inflammatory condition is e.g. dry skin or atopic or contact dermatitis.

Pimecrolimus being anti-inflammatory and having excellent skin penetration but only minimal skin permeation properties, it is not having significant systemic side effects when applied topically on skin, and the soothing effect of emollients complements its anti-inflammatory action on inflamed skin.

"Treatment" as used herein refers in particular to use for preferably alleviating an existing condition, namely curative treatment, although the invention also contemplates prophylactic use in conditions where a high probablity of inflammation exists.

Synergy is e.g. calculated as described in Berenbaum, Clin. Exp. Immunol. 28 (1977) 1, using an interaction term to correct for differences in mechanism between the two

drugs, as described in Chou et al., Transpl. Proc. 26 (1994) 3043. The index of synergy is calculated as:

$$\frac{\text{dose of A}}{A_E} + \frac{\text{dose of B}}{B_E} + \frac{\text{(dose of A) x (dose of B)}}{A_E \times B_E}$$

in which the doses of the compounds A and B represent those used in a particular combination, and A_E and B_E are the individual doses of A and B respectively giving the same effect. If the result is less than 1, there is synergy; if the result is 1, the effect is additive; if the result is greater than 1, A and B are antagonistic. By plotting an isobologram of dose of A / A_E vs. dose of B / B_E the combination of maximum synergy can be determined. The synergistic ratio expressed in terms of the ratio by weight of the two compositions at synergistic amounts along the isobologram, especially at or near the point of maximum synergy, can then be used to determine formulations containing an optimally synergistic ratio of the two compounds.

Activity may e.g. be determined in known assay models for testing the activity of the individual components of the compositions.

The invention also provides products and methods for co-administration of a macrolide T-cell immunomodulator or immunosuppressant, e.g. 33-epichloro-33-desoxy-ascomycin or 5,6-dehydroascomycin, and an emollient, e.g. dimethicone, at synergistically effective dosages, e.g.:

- a method of treatment or prevention of a dermatological or mucosal disease such as dry skin or atopic or contact dermatitis in a subject suffering from or at risk for such condition, comprising co-administering synergistically effective amounts of a composition of the invention;
- the use of a macrolide T-cell immunomodulator or immunosuppressant in the manufacture of a medicament for co-administration in synergistically effective amounts with an emollient;
- the use of an emollient in the manufacture of a medicament for co-administration in synergistically effective amounts with a macrolide T-cell immunomodulator or immunosuppressant;
- a kit of parts comprising a macrolide T-cell immunomodulator or immunosuppressant and an emollient in separate unit dosage forms, preferably wherein the unit dosage forms are suitable for administration of the component compounds in synergistically effective amounts, together with instruction for use, optionally with further means for facilitating compliance with the administration of the component compounds, e.g. a label or drawings;

- the use of a macrolide T-cell immunomodulator or immunosuppressant in the manufacture of a pharmaceutical kit which is to be used for facilitating co-administration with an emollient;
- the use of an emollient in the manufacture of a pharmaceutical kit which is to be used for facilitating co-administration with a macrolide T-cell immunomodulator or immunosuppressant;
- a macrolide T-cell immunomodulator or immunosuppressant and an emollient as a combined pharmaceutical preparation for simultaneous, separate or sequential use, preferably in synergistically effective amounts, e.g. for the treatment or prevention of a dermatological or mucosal disease such as dry skin or atopic or contact dermatitis;
- a pharmaceutical composition comprising a macrolide T-cell immunomodulator or immunosuppressant in combination or association with an emollient, e.g. in synergistically effective amounts, together with at least one pharmaceutically acceptable diluent or carrier, e.g. for use in treatment or prevention of a dermatological or mucosal disease such as dry skin or atopic or contact dermatitis; and
- a process for the preparation of a composition of the invention comprising mixing a macrolide T-cell immunomodulator or immunosuppressant and an emollient, in combination or association with at least one pharmaceutically acceptable diluent or carrier.

By "synergistically effective amounts" is meant an amount of macrolide T-cell immunomodulator or immunosuppressant and an amount of emollient which are individually below their respective effective dosages for a relevant indication, but which are pharmaceutically active on co-administration, e.g. in a synergistic ratio, for example as calculated above. Furthermore, "synergistically effective amounts" may mean an amount of macrolide T-cell immunomodulator or immunosuppressant and an amount of emollient which are individually equal to their respective effective dosages for a relevant indication, and which result in a more than additive effect.

The molar amount of macrolide T-cell immunomodulator or immunosuppressant present is from roughly similar to, to significantly less than the amount of emollient, preferably half as much or less. Synergistic ratios of macrolide T-cell immunomodulator or immunosuppressant to emollient by weight are thus suitably from about 10:1 to about 1:50, preferably from about 5:1 to about 1:20, most preferably from about 1:1 to about 1:15, e.g. about 1:12.

The compositions of the invention can be administered as a free combination, or can be formulated into a fixed combination, which greatly enhances the convenience for the patient.

Absolute dosages of the compounds will vary depending on a number of factors, e.g. the individual, the route of administration, the desired duration, the rate of release of the active agent and the nature and severity of the condition to be treated. For example, the amount of active agents required and the release rate thereof may be determined on the basis of known in vitro and in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect.

For example, in prevention and treatment of a dermatological or mucosal disease such as dry skin or atopic or contact dermatitis, an initial dosage of about 2-3 times the maintenance dosage is suitably administered, followed by a daily dosage of about 2-3 times the maintenance dosage for a period of from one to two weeks, and subsequently the dose is gradually tapered down at a rate of about 5 % per week to reach the maintenance dosage.. In general, synergistically effective amounts of 33-epichloro-33-desoxyascomycin and dimethicone on oral administration for use in prevention and treatment of dry skin or atopic or contact dermatitis in larger animals, e.g. man, are amounts of pimecrolimus of up to about 2 mg/kg/day, e.g. from about 0.01 mg/kg/day to about 2 mg/kg/day, preferably about 0.5 mg/kg/day, in combination or co-administration with amounts of dimethicone of up to about 50 mg/kg/day, e.g. from about 0.25 mg/kg/day to about 50 mg/kg/day, preferably about 2.5 mg/kg/day, in a synergistic ratio, as described. Suitable unit dosage forms for oral co-administration of these compounds thus may contain on the order of from about 0.5 mg to about 100 mg, preferably about 3 mg to about 30 mg of 33-epichloro-33-desoxyascomycin, and from about 10 mg to about 3000 mg, preferably about 50 mg to about 500 mg of dimethicone. The daily dosage for oral administration is preferably taken in a single dose, but may be spread out over two, three or four dosages per day. For i.v. administration, the effective dosage is lower than that required for oral administration, e.g. about one fifth the oral dosage.

By "co-administration" is meant administration of the components of the compositions of the invention together or at substantially the same time, e.g. within fifteen minutes or less, either in the same vehicle or in separate vehicles, so that upon oral

administration, for example, both compounds are present simultaneously in the gastrointestinal tract. However, upon topical application, administration of the components may also be separated by a time interval of at least several hours, e.g. 6 hours or 12 hours. Preferably, the compounds are administered as a fixed combination, preferably topically.

The compositions of the invention include compositions suitable for administration by any conventional route, in particular compositions suitable for administration either enterally, for example, orally, e.g. in the form of solutions for drinking, tablets or capsules, or parenterally, e.g. in the form of injectable solutions or suspensions; or topically, e.g. for the treatment of inflammatory conditions of the skin or mucosae, e.g. in the form of a dermal cream, ointment, ear drops, mousse, shampoo, solution, lotion, gel, emulgel or like preparation, e.g. in a concentration of from about 0.1 % to about 2 %, preferably about 1 % by weight of each component, especially in combination or association with penetration enhancing agents, as well as for application to the eye, e.g. in the form of an ocular cream, gel or eye-drop preparation, for treatment of inflammatory conditions of the lungs and airways, e.g. in the form of inhalable compositions, and for mucosal application, e.g. in the form of vaginal tablets.

The compositions of the invention are suitably emulsions, microemulsions, emulsion preconcentrates or microemulsion preconcentrates, or solid dispersions, especially water-in-oil microemulsion preconcentrates or oil-in-water microemulsions, comprising the macrolide T-cell immunomodulator or immunosuppressant and the emollient in a synergistic ratio.

The compositions of the invention can be prepared in conventional manner, e.g. by mixing a macrolide T-cell immunomodulator or immunosuppressant and an emollient, in combination or association with at least one pharmaceutically acceptable diluent or carrier.

The active agent components may be in free form or pharmaceutically acceptable salt form as appropriate.

While the invention primarily contemplates combination or association of just two pharmaceutically and/or cosmetically active components, it does not exclude the presence of further pharmaceutically and/or cosmetically active agents, e.g. one further active agent, such as an antiseptic, as far as they do not contradict the purpose of the present invention.

The following Examples illustrate the invention. The compounds are in free, i.e. neutral or base form unless specified otherwise.

Example 1: Cream (protective hydrophobic film)

Component	Amount (g)
33-Epichloro-33-desoxyascomycin	1.00
dimethicone	5.00
triglycerides, medium chain	15.00
oleyl alcohol	10.00
sodium cetylstearyl sulfate	1.00
cetyl alcohol	4.00
stearyl alcohol	4.00
glyceryl monostearate	2.00
benzyl alcohol	1.00
propylene glycol	5.00
citric acid	0.05
sodium hydroxide	*
water	ad 100.0

* amount required to adjust pH to 5.5

Preparation is according to conventional manufacturing procedures for an emulsion. The ascomycin derivative and dimethicone are added to the heated homogeneous oily phase which contains triglycerides medium chain, oleyl alcohol, sodium cetylstearyl sulfate, cetyl alcohol , stearyl alcohol and glyceryl monostearate. In parallel, the water phase containing the remaining ingredients is heated at the same temperature as the oily phase. The oily phase is added to the water phase and homogeneisation is performed. The resultant cream is cooled to room temperature.

Example 2: Cream (with a humectant)

The composition is as for Example 1, whereby dimethicone 5.00 g is replaced with glycerol 3.00 g, which for preparation is included in the water phase in place of the oily phase.

Example 3: Cream (semi-occlusive)

The composition is as for Example 1, whereby dimethicone 5.00 g is replaced with isostearyl isostearate 4.00 g.

Example 4: Ointment (protective hydrophobic film)

Component	Amount (g)
33-Epichloro-33-desoxyascomycin	1.00
dimethicone	5.00
oleyl alcohol	10.00
hexylene glycol	10.00
microcrystalline wax	5.00
white vaseline	ad 100.0

Preparation is according to conventional manufacturing procedures. The ascomycin is added to the heated homogeneous oily phase which contains dimethicone and the remaining ingredients. After homogeneisation the resultant ointment is cooled to room temperature.

Example 5: Solution (protective hydrophobic film)

Component	Amount (g)
33-Epichloro-33-desoxyascomycin	1.00
dimethicone	5.00
triglycerides, medium chain	10.00
oleyl alcohol	10.00
liquid paraffin	ad 100.0

Preparation is according to conventional manufacturing procedures and is as described under Example 4.

Example 6: Liquid emulsion (with a humectant)

Component	Amount (g)
33-Epichloro-33-desoxyascomycin	1.00
glycerol	3.00
triglycerides, medium chain	15.00
oleyl alcohol	10.00
glyceryl monooleate	2.00
Tween 80	4.00
benzyl alcohol	1.00
propylene glycol	5.00
citric acid	0.05
sodium hydroxide	*
water	ad 100.0

* amount required to adjust pH to 5.5

Preparation is according to conventional manufacturing procedures. The ascomycin is added to the heated homogeneous oily phase which contains triglycerides medium chain, oleyl alcohol and glyceryl monooleate. In parallel, the water phase containing glycerol and the remaining ingredients is heated at the same temperature as the oily phase. The oily phase is added to the water phase and homogeneisation is performed. The resultant emulsion is cooled to room temperature.

Example 7: Liquid emulsion (semi-occlusive)

As for Example 6, whereby glycerol 3.00 g is replaced with isostearyl isostearate 4.00 g, which for preparation is included in the oily phase in place of the water phase.

Claims:

1. A pharmaceutical composition comprising a macrolide T-cell immunomodulator or immunosuppressant in combination or association with an emollient, together with at least one pharmaceutically acceptable diluent or carrier.

2. A composition according to claim 1 comprising 33-epichloro-33-desoxyascomycin in combination or association with dimethicone, glycerol or isostearyl isostearate.

3. A method of treatment of a dermatological or mucosal disease such as dry skin or atopic or contact dermatitis in a subject suffering from or at risk for such condition, comprising co-administering a synergistically effective amount of a composition according to claim 1.

4. A process for the preparation of a composition according to claim 1 comprising mixing a macrolide T-cell immunomodulator or immunosuppressant and an emollient, in combination or association with at least one pharmaceutically acceptable diluent or carrier.

5. A kit of parts comprising a macrolide T-cell immunomodulator or immunosuppressant and an emollient in separate unit dosage forms, together with instructions for use.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/003513

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/435 A61K31/436 A61K47/02 A61K47/10 A61K47/14 A61K47/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/13249 A (SANDOZ AG ; SCHMOOK FRITZ (AT); POPP XUE PING (CH); JACKMAN MARTIN (CH) 9 May 1996 (1996-05-09) page 1 - page 15	1-5
X	WO 00/32234 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); KRIWET KATRIN (DE); R) 8 June 2000 (2000-06-08) page 1 - page 13	1-5

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
18 August 2004	25/08/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Kling, I

Form PCT/ISA/210 (second sheet) (January 2004)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KAPP A ET AL: "LONG-TERM MANAGEMENT OF ATOPIC DERMATITIS IN INFANTS WITH TOPICAL PIMECROLIMUS, A NONSTEROID ANTI-INFLAMMATORY DRUG" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 110, no. 2, August 2002 (2002-08), pages 277-284, XP009032310 ISSN: 0091-6749 the whole document	1-5
X	WO 97/25977 A (CIBA GEIGY AG ; TIEMESSEN HARRY (DE)) 24 July 1997 (1997-07-24) page 1 - page 16	1-5
X	EP 0 812 588 A (YOSHITOMI PHARMACEUTICAL) 17 December 1997 (1997-12-17) the whole document	1-5
X	EP 1 273 288 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH)) 8 January 2003 (2003-01-08) page 2, paragraph 1 - page 7, paragraph 3	1-5
X	GB 2 327 610 A (NOVARTIS AG) 3 February 1999 (1999-02-03) page 1 - page 5	1-5
Y	EP 1 064 942 A (FUJISAWA PHARMACEUTICAL CO) 3 January 2001 (2001-01-03) page 2 - page 11	1-5
Y	US 2002/044967 A1 (IBUKI RINTA ET AL) 18 April 2002 (2002-04-18) page 1, left-hand column - page 8, left-hand column	1-5
P,X	WO 2004/016289 A (NOVARTIS PHARMA GMBH ; NOVARTIS AG (CH); SEKKAT NABILA (CH); KRIWET KA) 26 February 2004 (2004-02-26) the whole document	1-5
P,X	WO 03/074054 A (NOVARTIS PHARMA GMBH ; NOVARTIS AG (CH); BABIOLE SAUNIER MAGGY (FR); B) 12 September 2003 (2003-09-12) the whole document	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/003513

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9613249 A	09-05-1996	AT 214593 T	15-04-2002
		AU 714254 B2	23-12-1999
		AU 3845195 A	23-05-1996
		AU 5833699 A	06-01-2000
		BR 9509530 A	14-10-1997
		CA 2200966 A1	09-05-1996
		CN 1401325 A	12-03-2003
		CN 1162259 A ,B	15-10-1997
		CY 2211 A	08-11-2002
		CZ 9701232 A3	13-08-1997
		CZ 290219 B6	12-06-2002
		DE 19581804 T0	22-01-1998
		DE 69525957 D1	25-04-2002
		DE 69525957 T2	14-11-2002
		DK 786986 T3	29-04-2002
		WO 9613249 A1	09-05-1996
		EP 1147766 A2	24-10-2001
		EP 0786986 A1	06-08-1997
		ES 2173978 T3	01-11-2002
		FI 971018 A	18-04-1997
		GB 2308546 A ,B	02-07-1997
		HU 77140 A2	02-03-1998
		JP 10508588 T	25-08-1998
		NO 971951 A	25-04-1997
		NZ 295170 A	25-02-1999
		NZ 331824 A	28-01-2000
		PL 319599 A1	18-08-1997
		PL 185320 B1	30-04-2003
		PT 786986 T	31-07-2002
		SI 786986 T1	30-06-2002
		SK 52097 A3	10-09-1997
		US 2001031769 A1	18-10-2001
		CY 2212 A	08-11-2002
		GB 2327610 A ,B	03-02-1999
		PL 184908 B1	31-01-2003
		RU 2181592 C2	27-04-2002
WO 0032234 A	08-06-2000	AU 767156 B2	30-10-2003
		AU 1656900 A	19-06-2000
		BR 9915861 A	21-08-2001
		CA 2350884 A1	08-06-2000
		CN 1329507 T	02-01-2002
		CZ 20011908 A3	12-09-2001
		WO 0032234 A1	08-06-2000
		EP 1135163 A1	26-09-2001
		HU 0104413 A2	28-03-2002
		JP 2002531419 T	24-09-2002
		NO 20012624 A	09-07-2001
		NZ 511687 A	31-10-2003
		PL 348750 A1	03-06-2002
		SK 7622001 A3	06-11-2001
		TR 200101547 T2	22-10-2001
		US 2001051650 A1	13-12-2001
		ZA 200104529 A	04-06-2002
WO 9725977 A	24-07-1997	AT 239449 T	15-05-2003
		AU 1543497 A	11-08-1997
		CA 2240339 A1	24-07-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/003513

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9725977 A		DE 69721729 D1	12-06-2003
		DE 69721729 T2	11-12-2003
		DK 874621 T3	01-09-2003
		WO 9725977 A1	24-07-1997
		EP 1273288 A1	08-01-2003
		EP 1273289 A1	08-01-2003
		EP 0874621 A1	04-11-1998
		ES 2199338 T3	16-02-2004
		HK 1015277 A1	08-04-2004
		JP 2000503655 T	28-03-2000
		JP 2004107350 A	08-04-2004
		PT 874621 T	30-09-2003
		US 6239102 B1	29-05-2001
EP 0812588 A	17-12-1997	AU 705320 B2	20-05-1999
		AU 1172997 A	28-07-1997
		EP 0812588 A1	17-12-1997
		IL 121625 A	13-09-2001
		NZ 324453 A	27-03-2000
		SK 115797 A3	04-02-1998
		US 6121329 A	19-09-2000
		CA 2213989 A1	10-07-1997
		CZ 9702704 A3	14-01-1998
		HU 9800034 A2	28-05-1999
		WO 9724112 A1	10-07-1997
		RU 2156127 C2	20-09-2000
		US 6197829 B1	06-03-2001
EP 1273288 A	08-01-2003	EP 1273288 A1	08-01-2003
		EP 1273289 A1	08-01-2003
		AT 239449 T	15-05-2003
		AU 1543497 A	11-08-1997
		CA 2240339 A1	24-07-1997
		DE 69721729 D1	12-06-2003
		DE 69721729 T2	11-12-2003
		DK 874621 T3	01-09-2003
		WO 9725977 A1	24-07-1997
		EP 0874621 A1	04-11-1998
		ES 2199338 T3	16-02-2004
		HK 1015277 A1	08-04-2004
		JP 2000503655 T	28-03-2000
		JP 2004107350 A	08-04-2004
		PT 874621 T	30-09-2003
		US 6239102 B1	29-05-2001
GB 2327610 A	03-02-1999	GB 2308546 A ,B	02-07-1997
		AT 214593 T	15-04-2002
		AU 714254 B2	23-12-1999
		AU 3845195 A	23-05-1996
		AU 5833699 A	06-01-2000
		BR 9509530 A	14-10-1997
		CA 2200966 A1	09-05-1996
		CN 1401325 A	12-03-2003
		CN 1162259 A ,B	15-10-1997
		CY 2211 A	08-11-2002
		CY 2212 A	08-11-2002
		CZ 9701232 A3	13-08-1997
		DE 19581804 T0	22-01-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/003513

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2327610 A		DE 69525957 D1	25-04-2002
		DE 69525957 T2	14-11-2002
		DK 786986 T3	29-04-2002
		WO 9613249 A1	09-05-1996
		EP 1147766 A2	24-10-2001
		EP 0786986 A1	06-08-1997
		ES 2173978 T3	01-11-2002
		FI 971018 A	18-04-1997
		HU 77140 A2	02-03-1998
		JP 10508588 T	25-08-1998
		NO 971951 A	25-04-1997
		NZ 295170 A	25-02-1999
		NZ 331824 A	28-01-2000
		PL 319599 A1	18-08-1997
		PL 184908 B1	31-01-2003
		PT 786986 T	31-07-2002
		RU 2181592 C2	27-04-2002
		SI 786986 T1	30-06-2002
		SK 52097 A3	10-09-1997
		US 2001031769 A1	18-10-2001
EP 1064942 A	03-01-2001	AT 269075 T	15-07-2004
		AU 749623 B2	27-06-2002
		AU 2856399 A	18-10-1999
		BR 9909201 A	14-11-2000
		CA 2322516 A1	07-10-1999
		DE 69918074 D1	22-07-2004
		EP 1064942 A1	03-01-2001
		HR 20000707 A1	31-12-2001
		HU 0101237 A2	28-09-2001
		NO 20004773 A	23-11-2000
		NZ 507211 A	25-07-2003
		RU 2214244 C2	20-10-2003
		SK 14392000 A3	12-03-2001
		US 6440458 B1	27-08-2002
		CN 1301157 T	27-06-2001
		EP 1421939 A1	26-05-2004
		ID 27825 A	26-04-2001
		WO 9949863 A1	07-10-1999
		PL 343096 A1	30-07-2001
		TR 200002771 T2	21-02-2001
		TW 570814 B	11-01-2004
		US 2003235614 A1	25-12-2003
		US 2002044967 A1	18-04-2002
		ZA 200004963 A	08-01-2002
US 2002044967 A1	18-04-2002	US 2003235614 A1	25-12-2003
		AT 269075 T	15-07-2004
		AU 749623 B2	27-06-2002
		AU 2856399 A	18-10-1999
		BR 9909201 A	14-11-2000
		CA 2322516 A1	07-10-1999
		CN 1301157 T	27-06-2001
		DE 69918074 D1	22-07-2004
		EP 1421939 A1	26-05-2004
		EP 1064942 A1	03-01-2001
		HR 20000707 A1	31-12-2001
		HU 0101237 A2	28-09-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/003513

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002044967 A1		ID 27825 A	26-04-2001
		WO 9949863 A1	07-10-1999
		NO 20004773 A	23-11-2000
		NZ 507211 A	25-07-2003
		PL 343096 A1	30-07-2001
		SK 14392000 A3	12-03-2001
		TR 200002771 T2	21-02-2001
		TW 570814 B	11-01-2004
		US 6440458 B1	27-08-2002
		ZA 200004963 A	08-01-2002
WO 2004016289 A	26-02-2004	WO 2004016289 A1	26-02-2004
WO 03074054 A	12-09-2003	WO 03074054 A1	12-09-2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087141 A1

(51) International Patent Classification[7]: A61K 31/435, 31/436, 47/02, 47/10, 47/14, 47/44

(21) International Application Number: PCT/EP2004/003513

(22) International Filing Date: 2 April 2004 (02.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0307866.4 4 April 2003 (04.04.2003) GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HIRSCH, Stefan** [DE/DE]; Theodor-Heuss-Strasse 21A, 79539 Lörrach (DE). **MAYER, Friedrich, Karl** [AT/CH]; Im Ziegelgarten 9, CH-4104 Oberwil (CH). **PAUL, Carle** [FR/FR]; 20, rue du Sundgau, F-68100 Mulhouse (FR). **SEKKAT, Nabila** [MA/CH]; Davidsbodenstrasse 34, CH-4056 Basel (CH). **WEISS, Carl-Martin** [DE/DE]; Ritterstrasse 57a, 79541 Lörrach-Haagen (DE).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectuel Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *with amended claims*

Date of publication of the amended claims: 6 January 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING AN IMMUNOSUPPRESSANT FOR USE IN THE TREATMENT OF SKIN DISEASES

(57) Abstract: Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an emollient such as dimethicone, glycerol or isostearyl isostearate are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as dry skin or atopic or contact dermatitis.

WO 2004/087141 A1

AMENDED CLAIMS

[received by the International Bureau on 15 October 2004 (15.10.04);
original claims 1, 2, 4, 5 replaced by amended claims 1, 2, 4, 5]

Patent Claims

1. A pharmaceutical composition comprising 33-epichloro-33-desoxyascomycin in combination or association with an emollient selected from the group consisting of dimethicone, glycerol and isostearylstearate together with at least one pharmaceutically acceptable diluent or carrier.

2. A pharmaceutical composition of claim 1 wherein the emollient is present in an amount from about 10% to about 5000% w/w of the amount of 33-epichloro-33-desoxyascomycin.

3. A method of treatment of a dermatological or mucosal disease in a subject suffering from such a disease comprising co-administering synergistically effective amounts of a composition of claim 1.

4. A process for the preparation of a composition of any one of claims 1 or 2 comprising mixing 33-epichloro-33-desoxyascomycin and an emollient selected from the group consisting of dimethicone, glycerol and isostearylstearate in combination or association with at least one pharmaceutically acceptable diluent or carrier.

5. A kit of parts comprising 33-epichloro-33-desoxyascomycin and an emollient selected from the group consisting of dimethicone, glycerol and isostearylstearate in separate unit dosage forms, together with instructions for use.